Science Explorer Back to mapMap

Most cited papers from Najít Technologies (United States)

Najít Technologies (United States)

What are the most cited papers from Najít Technologies (United States)?

The most cited paper from Najít Technologies (United States) is "Mechanisms that determine plasma cell lifespan and the duration of humoral immunity" (Ian J. Amanna, Mark K. Slifka, 2010), with 351 citations. Next come "Contributions of humoral and cellular immunity to vaccine-induced protection in humans" (270) and "Plasma cell survival in the absence of B cell memory" (215).

Showing 37 of 37 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Mechanisms that determine plasma cell lifespan and the duration of humoral immunity Ian J. Amanna, Mark K. Slifka · Immunological Reviews ReviewOpen access 15 Jun 2010 351
2 Contributions of humoral and cellular immunity to vaccine-induced protection in humans Ian J. Amanna, Mark K. Slifka · Virology Open access 9 Jan 2011 270
3 Plasma cell survival in the absence of B cell memory Erika Hammarlund, Archana Thomas, Ian J. Amanna et al. · Nature Communications Open access 20 Nov 2017 215
4 Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses Mark K. Slifka, Ian J. Amanna · Frontiers in Immunology Open access May 2019 148
5 Heterogeneity and longevity of antibody memory to viruses and vaccines Alice Antia, Hasan Ahmed, Andreas Handel et al. · PLoS Biology Open access 10 Aug 2018 147
6 Development of a new hydrogen peroxide–based vaccine platform Ian J. Amanna, Hans Peter Raué, Mark K. Slifka · Nature Medicine Open access 27 May 2012 132
7 How advances in immunology provide insight into improving vaccine efficacy Mark K. Slifka, Ian J. Amanna · Vaccine Open access 5 Apr 2014 130
8 Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis Erika Hammarlund, Archana Thomas, Elizabeth A. Poore et al. · Clinical Infectious Diseases Open access 21 Mar 2016 113
9 Optimization of Peptide-Based ELISA for Serological Diagnostics: A Retrospective Study of Human Monkeypox Infection Melissa E. Dubois, Erika Hammarlund, Mark K. Slifka · Vector-Borne and Zoonotic Diseases Open access 4 Jan 2012 94
10 A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice Amelia K. Pinto, Justin M. Richner, Elizabeth A. Poore et al. · Journal of Virology Open access 6 Dec 2012 75
11 Questions regarding the safety and duration of immunity following live yellow fever vaccination Ian J. Amanna, Mark K. Slifka · Expert Review of Vaccines Open access 8 Jun 2016 65
12 Wanted, dead or alive: New viral vaccines Ian J. Amanna, Mark K. Slifka · Antiviral Research Open access 5 Sep 2009 63
13 Current trends in West Nile virus vaccine development Ian J. Amanna, Mark K. Slifka · Expert Review of Vaccines Open access Apr 2014 59
14 Successful Vaccines Ian J. Amanna, Mark K. Slifka · Current topics in microbiology and immunology Book chapterOpen access 2018 39
15 An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults Christopher W. Woods, Ana Maria Sanchez, Geeta Krishna Swamy et al. · Vaccine Open access 18 Jan 2019 35
16 Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting Bettie W. Kareko, Brian L. Booty, Chad Douglas Nix et al. · The Journal of Infectious Diseases Open access 15 Aug 2019 28
17 Development of a novel serological assay for the detection of mpox infection in vaccinated populations Jennifer L. Yates, Danielle Hunt, Karen E. Kulas et al. · Journal of Medical Virology Open access Oct 2023 27
18 Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine Benjamin K. Quintel, Archana Thomas, Danae E. Poer DeRaad et al. · Vaccine Open access 31 Dec 2018 26
19 Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine Elizabeth A. Poore, Dawn K. Slifka, Hans-Peter Raué et al. · Vaccine Open access 3 Dec 2016 24
20 Balancing the Efficacy and Safety of Vaccines in the Elderly Ian J. Amanna · Open Longevity Science Open access Jun 2012 24
21 Vaccine-mediated protection against Campylobacter -associated enteric disease Benjamin K. Quintel, Kamm Prongay, Anne D. Lewis et al. · Science Advances Open access 24 Jun 2020 23
22 Development of a next-generation chikungunya virus vaccine based on the HydroVax platform Dawn K. Slifka, Hans-Peter Raué, Whitney C. Weber et al. · PLoS Pathogens Open access 5 Jul 2022 20
23 Antiviral Immune Response After Live Yellow Fever Vaccination of a Kidney Transplant Recipient Treated With IVIG Mark K. Slifka, Erika Hammarlund, Matthew W. Lewis et al. · Transplantation Open access 7 May 2013 19
24 Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques Sara M. Hendrickson, Archana Thomas, Hans-Peter Raué et al. · Nature Communications Open access 26 Jun 2023 17
25 Reduced infant rhesus macaque growth rates due to environmental enteric dysfunction and association with histopathology in the large intestine Sara M. Hendrickson, Archana Thomas, Kamm Prongay et al. · Nature Communications Open access 11 Jan 2022 14
26 A Management Accounting Framework Gary Cokins · Journal of Corporate Accounting & Finance Nov 2001 14
27 A Flow Cytometry-Based Assay for Quantifying Non-Plaque Forming Strains of Yellow Fever Virus Erika Hammarlund, Ian J. Amanna, Melissa E. Dubois et al. · PLoS ONE Open access 19 Sep 2012 12
28 Development of a virulent O’nyong’nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine Whitney C. Weber, Zachary J. Streblow, Takeshi F. Andoh et al. · PLoS neglected tropical diseases Open access 17 Mar 2025 8
29 Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model Ian J. Amanna, Archana Thomas, Flora Engelmann et al. · Cell Reports Medicine Open access Jul 2024 8
30 Active Circulation of Corynebacterium ulcerans among Nonhuman Primates Archana Thomas, Ariel M Slifka, Sara M. Hendrickson et al. · Microbiology Spectrum Open access 12 Jul 2022 8
31 Antibody-Mediated Protection against Respiratory Viral Infection Melissa E. Dubois, Paul Yoshihara, Mark K. Slifka · Seminars in Respiratory and Critical Care Medicine 2005 5
32 Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to development Randall J. Nett, Aaron C. Brault, Amy J. Lambert et al. · Vaccine Open access 5 Nov 2025 3
33 Lessons learned from successful implementation of tetanus and diphtheria vaccination programs Mark K. Slifka, Archana Thomas, Lina Gao et al. · Clinical Microbiology Reviews Open access 15 Jul 2025 3
34 Analysis of COVID-19 Transmission: Low Risk of Presymptomatic Spread? Mark K. Slifka, William B. Messer, Ian J. Amanna · Archives of Pathology & Laboratory Medicine Open access 5 Jun 2020 2
35 Dynamic Inventory Optimization and Cost Reduction Using Motif Knowledge Heterogeneous Dollmaker Graph Attention Network for Global Supply Chain Efficiency Karri Sairamakrishna BuchiReddy, Lohith Sai Andra, Banze Ryan et al. · Research Square PreprintOpen access 19 Feb 2026 0
36 The Keys to Implementing Activity-Based Management Mohan Nair · Journal of Corporate Accounting & Finance Mar 2000 0
37 Correlates of Vaccine-Induced Immunity: Historical Perspectives and Future Challenges Ian J. Amanna Book chapter 2012 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.